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Abstract
 
Interleukin-10 (IL-10) is a potent deactivator of myeloid cells that limits the intensity and dura-
tion of immune and inflammatory responses. The activity of IL-10 can be suppressed during
inflammation, infection, or after allogeneic tissue transplantation. We investigated whether
inflammatory factors suppress IL-10 activity at the level of signal transduction. Out of many
factors tested, only ligation of Fc receptors by immune complexes inhibited IL-10 activation of
the Jak-Stat signaling pathway. IL-10 signaling was suppressed in rheumatoid arthritis joint
macrophages that are exposed to immune complexes in vivo. Activation of macrophages with
interferon-
 
 
 
 was required for Fc receptor–mediated suppression of IL-10 signaling, which re-
sulted in diminished activation of IL-10–inducible genes and reversal of IL-10–dependent
suppression of cytokine production. The mechanism of inhibition involved decreased cell sur-
face IL-10 receptor expression and Jak1 activation and was dependent on protein kinase C
delta. These results establish that IL-10 signaling is regulated during inflammation and identify
Fc receptors and interferon-
 
 
 
 as important regulators of IL-10 activity. Generation of mac-
rophages refractory to IL-10 can contribute to pathogenesis of inflammatory and infectious
diseases characterized by production of interferon-
 
 
 
 and immune complexes.
Key words: interleukin 10 • Fc receptor • signal transduction • Jak-Stat • macrophage
 
Introduction
 
IL-10 is predominantly an immunosuppressive and antiin-
flammatory cytokine and is a potent deactivator of dendritic
cells and macrophages (for a review, see reference 1). IL-10
plays a critical role in limiting tissue injury during infec-
tions by limiting the duration and intensity of immune and
inflammatory reactions (1–5). In the absence of IL-10,
mice spontaneously develop inflammatory bowel and skin
disease (6). IL-10 has been shown to suppress inflammation
in many experimental models of inflammatory disease,
including collagen induced arthritis, pancreatitis, uveitis,
keratitis, hepatitis, peritonitis, lung injury, and neural injury
(1). IL-10 enhances heart allograft survival and suppresses
graft versus host disease if given before bone marrow trans-
plantation (7, 8).
It has been long appreciated that the amount and timing
of IL-10 production is tightly regulated, consistent with its
important role in determining the balance between effec-
tive clearance of infectious pathogens and collateral tissue
damage (1, 9–11). More recently, evidence is emerging
that the activity of IL-10 is also regulated during the course
of an immune response. Examples include suppression of
IL-10 activity during chronic infection with the LP-BM5
retrovirus (12) or during experimental endotoxemia (13).
In contrast to treatment before transplantation, IL-10 treat-
ment after transplantation is ineffective at suppressing heart
allograft survival and graft versus host disease after bone
marrow transplantation (14, 15). IL-10 activity also appears
to be blunted during chronic inflammatory diseases, as IL-10
was not effective in suppressing cytokine production in
monocytes and macrophages derived from patients with
SLE or rheumatoid arthritis (RA)
 
*
 
 (16, 17). Thus, modula-
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 DAG, diacyl glycerol; EMSA, electro-
phoretic mobility shift assay; IC, immune complex; PKC, protein kinase
C; RA, rheumatoid arthritis; SOCS, suppressors of cytokine signaling;
STAT, signal transducer and activator of transcription.T
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tion of IL-10 activity plays a role in regulation of the inten-
sity and chronicity of immune and inflammatory reactions.
The factors and mechanisms that regulate IL-10 activity are
not known.
Fc receptors (FcRs) bind the Fc region of Igs and are ac-
tivated by cross-linking that occurs after ligation by multi-
merized Igs, such as those present in immune complexes or
on opsonized pathogens (for a review, see reference 18).
Ligation of myeloid cell FcRs specific for IgG, termed
Fc
 
 
 
Rs, activates cellular effector functions, including
phagocytosis of opsonized pathogens, endocytic clearance of
immune complexes, and production of cytokines, chemo-
kines, and reactive oxygen intermediates. Fc
 
 
 
Rs are im-
portant effector molecules of humoral immunity and have
been implicated in the pathogenesis of inflammatory disor-
ders characterized by the presence of immune complexes
(ICs), such as SLE (19). Fc
 
 
 
Rs contribute to SLE patho-
genesis by mediating activation of cells by ICs, and second-
ary to defective clearance of ICs in patients with Fc
 
 
 
R
polymorphisms (19, 20). Lupus-prone mice deficient for
functional activating Fc
 
 
 
Rs, Fc
 
 
 
RI and Fc
 
 
 
RIII, do not
develop end organ damage or glomerulonephritis, despite
high levels of IC deposition (21). ICs are present in joint
fluid and cartilage in RA (22, 23), and recently there has
been a revival of interest in the role of B cells, autoantibod-
ies, and antibody-dependent effector mechanisms in the
pathogenesis of RA (24). An important role for Fc
 
 
 
Rs in
RA pathogenesis is supported by the linkage of Fc
 
 
 
R poly-
morphisms with RA (25), and the striking effects of Fc
 
 
 
R
deficiency on disease incidence and severity in several ani-
mal models of inflammatory arthritis (18, 26–33).
At sites of inflammation, cells are exposed to multiple
pro- and antiinflammatory factors. The current paradigm
suggests that the balance between pro- and antiinflamma-
tory factors regulates the severity of chronic inflammatory
diseases such as RA. We investigated whether suppression
of IL-10 signal transduction corresponded to a mechanism
by which IL-10 activity, and thus cytokine balance, are
regulated during inflammation. We found that IL-10 signal
transduction is suppressed in RA and a block in IL-10 sig-
naling is induced by the combination of IFN-
 
  
 
and ICs,
inflammatory factors that are expressed in several chronic
inflammatory diseases and infections. These results suggest
that dysregulation of IL-10 signaling contributes to patho-
genesis of inflammatory/autoimmune diseases characterized
by the production of IFN-
 
 
 
 and ICs, such as RA and SLE.
 
Materials and Methods
 
Cell Isolation and Tissue Culture.
 
Monocytes were obtained
from peripheral blood or RA synovial fluid mononuclear cells or
synovial tissue, using anti-CD14 magnetic beads, as recom-
mended by the manufacturer (Miltenyi Biotec), and were 
 
 
 
97%
pure as verified using flow cytometry, as described previously
(34). Monocytes were cultured for 2 d in RPMI 1640 medium
supplemented with 10% fetal bovine serum (Hyclone) with ei-
ther M-CSF (20 ng/ml) or IFN-
 
 
 
 (100 U/ml) (R&D Systems).
RA synovial tissue macrophages were obtained by digesting tis-
sues using collagenase and dispase, as described previously (35),
and selection using anti-CD14 magnetic beads. All patients ful-
filled revised ACR criteria for the diagnosis of RA, and the pro-
tocol was approved by the Hospital for Special Surgery institu-
tional review board. Murine C57BL/6 thioglycollate-elicited
macrophages were obtained by peritoneal lavage 5 d after injec-
tion of thioglycollate and purified by adherence. The protocol
was approved by the Hospital for Special Surgery animal care and
use committee.
 
Phagocytosis Assays.
 
E-IgG were prepared using oxen eryth-
rocytes (Ox Es) that were opsonized with human IgG1, murine
IgG, or rat mAb 2.4G2 against murine Fc
 
 
 
RII and Fc
 
 
 
RIII, us-
ing a streptavidin-biotin bridge system and labeled with the fluo-
rescent dye PKH26, as described previously (36). Typically, each
E-IgG showed a mean fluorescence of 100 channels over back-
ground. Es or E-IgGs were incubated with adherent macrophages
for 1 h at a ratio of 20:1. Extracellular Es and E-IgGs were lysed
using water and intracellular fluorescence of macrophages was
measured using flow cytometry. Typically, 
 
 
 
85% of macro-
phages were phagocytic. The phagocytosis index was calculated
by multiplying the mean fluorescence intensity by the fraction of
cells that were phagocytic, as described previously (36).
 
Electrophoretic Mobility Shift Assay and Immunoblotting.
 
Cells
were stimulated with cytokines (IL-10, 20 ng/ml; IFN-
 
 
 
, 8 ng/
ml) for 10 min. Cell extracts were obtained, and protein levels
quantitated using the Bradford assay (Bio-Rad Laboratories), as
described previously (34). 5 
 
 
 
g of cell extracts were incubated for
15 min at room temperature with 0.5 ng of 
 
32
 
P-labeled double
stranded high affinity sis-inducible element (hSIE) oligonucle-
otide 5
 
 
 
-GTCGACATTTCCCGTAAATC-3
 
 
 
 that binds Stat1
and Stat3, as confirmed by supershift experiments (37, 38), in a
15 
 
 
 
l binding reaction containing 40 mM NaCl and 2 
 
 
 
g of
poly-dI-dC (Amersham Biosciences), and complexes were re-
solved on nondenaturing 4.5% polyacrylamide gels. For immu-
noblotting, 15 
 
 
 
g of cell extracts were fractionated on 7.5% poly-
acrylamide gels using SDS-PAGE, transferred to polyvinylidene
fluoride membranes (Millipore), incubated with specific antibod-
ies, and enhanced chemiluminescence was used for detection.
mAbs against Stat1 (clone 1), Stat3 (clone 84), Jak1 (clone 73),
and PKC
 
 
 
 (clone 14) were obtained from BD Transduction
Laboratories, and anti–IL-10R1 antibodies were obtained from
Santa Cruz Biotechnology, Inc. Phosphorylation-specific Stat1
(Tyr
 
701
 
), Stat3 (Tyr
 
703
 
), and PKC
 
 
 
 (Ser
 
643
 
) antibodies were pur-
chased from Cell Signaling Technology. Phosphorylation specific
anti-Jak1 (Tyr
 
1022/1023
 
) was from Biosource International.
 
ELISA.
 
Es or E-IgGs were added 1 h before addition of IL-
10 (20 ng/ml) and LPS (100 ng/ml) and supernatants were har-
vested after an additional 16 h. ELISAs were performed using
paired antibody sets, as recommended by the manufacturer
(R&D Systems).
 
Analysis of mRNA.
 
For real time, quantitative PCR, DNA-
free RNA was obtained using the RNeasy Mini Kit from
QIAGEN with DNase treatment, and 1 
 
 
 
g of total RNA was re-
verse-transcribed using random hexamers and MMLV reverse
transcriptase. Real time PCR was performed in triplicate using
the iCycler iQ thermal cycler and detection system (Bio-Rad
Laboratories), and the PCR Core Reagents kit (Applied Biosys-
tems), with 500 nM primers; the final Mg
 
2
 
 
 
 concentration was
adjusted to 4 mM, as described previously (34). mRNA amounts
were normalized relative to GAPDH mRNA. When reverse
transcriptase was omitted, threshold cycle number increased by at
least 10, signifying lack of genomic DNA contamination or non-
specific amplification, and the generation of only the correct sizeT
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amplification products was confirmed using agarose gel elec-
trophoresis. Oligonucleotide primers used are as following:
SOCS3: 5
 
 
 
-CACTCTTCAGCATCTCTGTCGGAAG-3
 
 
 
 and
5
 
 
 
-CATAGGAGTCCAGGTGGCCGTTGAC-3
 
 
 
; TSG14: 5
 
 
 
-
TACTAGACTTTATGCCATGGTGCTT-3
 
 
 
 and 5
 
 
 
-TTA-
TCTGACAGAGACAGCATTAA-3
 
 
 
; KIAA0307: 5
 
 
 
-GAC-
GGCTTGCTTCATCTAACAATCT-3
 
 
 
 and 5
 
 
 
-GTCCAC-
TGACACCTGCTTATGAAAT-3
 
 
 
; GAPDH: 5
 
 
 
-GTGAA-
GGTCGGAGTCAAC-3
 
 
 
 and 5
 
 
 
-TGGAATTTGCCATGG-
GTG-3
 
 
 
.
 
Flow Cytometry.
 
Flow cytometry was performed as described
previously (34). The binding of IL-10 to cell surface IL-10Rs was
measured using a Fluorokine kit according to the instructions of
the manufacturer (R&D Systems).
 
Results
 
IL-10 Signaling Is Inhibited by Fc
 
 
 
R Ligation.
 
We rea-
soned that inflammatory factors may inhibit IL-10 activity
by suppressing IL-10 signal transduction. Ligation of the
heterodimeric IL-10 receptor (IL-10R), consisting of IL-
10R1 and IL-10R2 subunits, results in the activation of re-
ceptor-associated Jak1 and Tyk2 protein tyrosine kinases,
and subsequent tyrosine phosphorylation and activation of
DNA binding of Stat3 and Stat1; in resting myeloid cells,
IL-10 activates primarily Stat3 (1, 39, 40). The effects of
various inflammatory factors, alone or in combination, on
IL-10 activation of STATs (signal transducer and activator
of transcription) were assessed using electrophoretic mobil-
ity shift assays (EMSAs) to measure STAT DNA binding
and immunoblotting to measure STAT tyrosine phosphor-
ylation in purified human monocytes that had been acti-
vated with IFN-
 
 
 
. As expected, in control macrophages
IL-10 activated STAT DNA binding to the hSIE oligonu-
cleotide that binds Stat1 and Stat3, and activated tyrosine
phosphorylation of Stat3 (Fig. 1 A, lane 2). IL-10 also con-
sistently activated Stat1 tyrosine phosphorylation in macro-
phages that had been activated by IFN-
 
 
 
, such as the cells
used in these experiments (Fig. 1 A, third panel). The sig-
nificance of Stat1 activation by IL-10 in macrophages is not
clear but Stat1 activation provides a signaling event that can
be monitored in addition to the activation of Stat3. Liga-
tion of Fc
 
 
 
Rs during phagocytosis of IgG-opsonized
erythrocytes (E-IgGs) nearly completely blocked IL-10 ac-
tivation of STAT DNA binding and Stat3 and Stat1 tyro-
sine phosphorylation (Fig. 1 A, lane 3). When the ratio of
E-IgGs to macrophages was decreased, inhibition of IL-10
signaling decreased in a dose dependent fashion that corre-
lated with diminished phagocytosis (Fig. 1 A). Stat3 and
Stat1 levels were comparable in all lanes (Fig. 1 A), indicat-
ing that E-IgGs induced a block in signal transduction, and
not degradation of STATs. In contrast to Fc
 
 
 
R ligation,
TNF-
 
 
 
, IL-1
 
 
 
, LPS, GM-CSF, and TGF-
 
 
 
 had minimal
effect upon IL-10–activated STAT DNA binding or tyro-
sine phosphorylation (Fig. 1, B and C). Phagocytosis or en-
docytosis were not required for inhibition of IL-10 signal-
ing, as inhibition occurred when Fc
 
 
 
Rs were cross-linked
with plate-bound IgG (Fig. 1 D). GM-CSF activation of
Stat5 was not affected by E-IgGs, indicating that Fc
 
 
 
R li-
gation did not nonspecifically inhibit cytokine signaling via
the Jak-STAT pathway (Fig. 1 E). Inhibition of IL-10 sig-
naling by E-IgGs was consistently observed in over 50 in-
dependent experiments using monocytes derived from dif-
ferent donors; of the other inflammatory factors tested,
none inhibited IL-10 signaling except for a weak and in-
Figure 1. IL-10 signaling is inhibited
after ligation of Fc Rs. Macrophages
were activated with IFN-  (100 U/ml)
for 2 d and then treated with various
factors for 1 h before addition of IL-10
(20 ng/ml) for 10 min. (A) E-IgGs were
added to macrophages in ratios that var-
ied from 20:1 (1 ) to 2.5:1, and STAT
activation was measured using EMSA
and immunoblotting. Phagocytosis in-
dex was measured using flow cytometry.
E, erythrocytes; E-IgG, erythrocytes op-
sonized with human IgG1. (B) STAT
activation was measured by EMSA using
the hSIE oligonucleotide. (C) Cell ex-
tracts were analyzed for tyrosine-phos-
phorylated Stat3 (pY-Stat3), and total
Stat3 protein using immunoblotting.
(D) Cells were added to culture wells
containing plate-bound IgG for 1 h be-
fore treatment with IL-10 for 10 min,
and levels of pY-Stat3 and Stat3 were
determined using immunoblotting. (E)
Activation of Stat5 by GM-CSF was an-
alyzed by immunoblotting.T
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consistent effect of IL-1. Production of IL-10 after ligation
of Fc
 
 
 
Rs was not detected in these experiments using an
ELISA that could detect 2 pg/ml of IL-10 (unpublished
data). The lack of IL-10 production does not contradict
previous reports (41, 42) where Fc
 
 
 
Rs induced IL-10 pro-
duction after LPS pretreatment, because we did not preac-
tivate cells with LPS. These results demonstrate that Fc
 
 
 
R
ligation inhibits IL-10 signaling, and suggest that Fc
 
 
 
Rs
trigger an inhibitory pathway that is not activated by TNF,
IL-1, LPS, GM-CSF, or TGF-
 
 
 
.
 
Inhibition of IL-10 Signaling In Vivo.
 
We investigated
whether IL-10 signaling is inhibited after ligation of Fc
 
 
 
Rs
in vivo in thioglycollate-elicited murine peritoneal mac-
rophages. Elicited macrophages were activated in vivo by
intraperitoneal injection of IFN-
 
 
 
 to achieve a fully acti-
vated state comparable to IFN-
 
 
 
–activated human mac-
rophages. When mice were injected intraperitoneally with
E-IgGs, activation of STAT DNA binding and tyrosine
phosphorylation by IL-10 in peritoneal macrophages was
suppressed (Fig. 2 A). These results suggest that IL-10 sig-
naling is modulated in vivo during the course of IC-medi-
ated inflammatory processes. RA is a chronic inflammatory
disease in which activated macrophages are exposed to im-
mune complexes in joints. Therefore, we compared IL-10
signaling in freshly isolated RA synovial tissue and fluid
macrophages with signaling in control blood-derived mac-
rophages (Fig. 2 B, a representative experiment is shown).
There were no significant differences in STAT activation
by IL-10 between freshly isolated monocytes and blood-
derived macrophages from normal donors that had been
cultured in M-CSF for 2, 5, or 7 d, and thus blood-derived
macrophages serve as a control for normal levels of IL-10
STAT activation in myeloid cells. IL-10 activated STAT
 
DNA binding in control cells on all occasions tested (35/
35). In contrast, IL-10 activated STAT DNA binding in
RA synovial tissue-derived macrophages in only 1/11 sam-
ples and in synovial fluid macrophages in 3/12 samples.
The differences in STAT activation were statistically signif-
icant (synovial tissue versus blood-derived macrophages,
P 
 
 
 
 0.001; synovial fluid versus blood-derived macrophages,
P 
 
  
 
0.01). STAT activation by IL-6 was also consistently
blocked in RA synovial macrophages (Fig. 2 B). IFN-
 
 
 
signaling was preserved in RA synovial macrophages, dem-
onstrating preferential suppression of IL-10 signaling (Fig. 2
B). Levels of Stat3 protein were comparable in RA and
control cells (Fig. 2 C), and thus differences in DNA bind-
ing could not be explained on the basis of lower STAT
protein levels. Diminished activation of STATs in RA syn-
ovial macrophages cannot be explained solely on the basis
of desensitization of IL-10 pathways by IL-10 present in
RA synovial fluid (
 
 
 
100 pg/ml; references 43 and 44) be-
cause: (a) IL-10 receptor occupancy by the levels of IL-10
present in RA synovial fluid would be very low, and
 
 
 
100–1,000-fold higher concentrations of IL-10 are re-
quired to saturate IL-10 receptors (43–45). (b) We did not
detect desensitization of the IL-10 pathway when macro-
phages were cultured for 7 d in saturating concentrations of
IL-10 (100 ng/ml, replenished every other day), isolated,
and stimulated exactly as was done with RA macrophages.
These results demonstrate that RA synovitis, which is char-
acterized by activation of macrophages and high levels of
synovial ICs, leads to suppression of IL-10 signaling.
 
Fc
 
 
 
R Ligation Inhibits IL-10 Biological Activity.
 
An im-
portant antiinflammatory function of IL-10 is the suppres-
sion of cytokine production (1). We assessed the physiologi-
cal significance of Fc
 
 
 
R-dependent inhibition of IL-10
signaling by examining the effects of Fc
 
 
 
R ligation on IL-10
inhibition of LPS-induced cytokine synthesis (Fig. 3 A). In
control macrophages incubated with Es, IL-10 strongly in-
hibited TNF-
 
 
 
 and IL-6 production. In contrast, when
macrophages were incubated with E-IgGs, IL-10 had no de-
tectable effect on TNF-
 
 
 
 production. E-IgGs also sup-
pressed the ability of IL-10 to inhibit IL-6 production (Fig. 3
A). We also assessed the effects of Fc
 
 
 
R ligation on IL-10
induction of gene expression. The expression of the SOCS3,
TSG14 (TNF-stimulated gene 14, also known as pentraxin-3
[46, 47]) and KIAA0307 genes that were consistently acti-
vated by IL-10 in control and IFN-
 
 –activated macrophages
(unpublished data) was examined. Incubation of mono-
cytes with E-IgGs completely blocked IL-10 induction of
SOCS3, TSG14, and KIAA0307 mRNA (Fig. 3 B). Thus,
inhibition of IL-10 signaling resulted in suppression of IL-10
biological activity and IL-10–dependent gene activation.
Inhibition of IL-10 Signaling Is Dependent upon Activation
State of Macrophages and on Specific Fc Rs. In many physi-
ological situations macrophages need to clear ICs or op-
sonized particles but remain responsive to IL-10, such that
excessive inflammation is prevented (48). Therefore, we
hypothesized that Fc R-mediated modulation of IL-10
signaling would be regulated, and would vary with the
physiological state of the macrophage. This hypothesis
Figure 2. Inhibition of IL-10
signaling in vivo. (A) Murine
thioglycollate-elicited peritoneal
macrophages were activated by
daily IP injections of 1,000 units
of IFN- , and 2 d later 50   106
E-IgGs were injected IP and
peritoneal cells were harvested
after 4 h. IL-10 activation of
STATs was assessed using EMSA
and immunoblotting. (B) Activa-
tion of STAT DNA binding by
IL-10 is suppressed in RA sy-
novial macrophages. STAT acti-
vation in freshly isolated control
and RA macrophages was mea-
sured by EMSA using the hSIE
oligonucleotide. A representative
experiment out of 23 RA sam-
ples analyzed is shown. (C) Stat3
protein levels were measured us-
ing immunoblotting.T
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was tested by comparing the effects of Fc R ligation in
M-CSF–differentiated and IFN- –activated macrophages. In
four independent experiments, E-IgGs were not effective
in inhibiting IL-10 signaling in M-CSF–differentiated mac-
rophages, relative to the near complete inhibition observed
in IFN- –activated cells (Fig. 4 A; a representative experi-
ment is shown). The M-CSF–cultured cells phagocytosed
E-IgGs at a comparable, or slightly higher, rate than IFN-
 –activated cells (unpublished data), indicating that differ-
ences in rates of phagocytosis did not explain the differ-
ences in inhibition of IL-10 signaling. Comparable results
were obtained when Fc Rs were ligated by plate-bound
IgG (Fig. 4 B). Thus, IFN-  activation of macrophages was
required for Fc R-mediated inhibition of IL-10 signaling
in vitro. We have not determined if IFN-  was required
for inhibition of IL-10 signaling in vivo (Fig. 2 A), and it is
possible that Fc R-mediated inhibition of IL-10 signaling
can occur in different macrophage stages of differentiation
or activation in the absence of IFN- .
As expected (18), flow cytometry showed that Fc RI
expression was elevated in IFN- –activated macrophages,
while expression of Fc RII and Fc RIII was comparable
in IFN- –activated and M-CSF-cultured cells (Fig. 4 C).
The roles of individual Fc Rs in inhibition of IL-10 signal-
ing were investigated by cross-linking Fc Rs with isoform-
specific F(ab ) fragments, followed by cross-linking with
goat F(ab )2 anti–mouse IgG. Cross-linking of Fc RI in-
hibited IL-10 induction of STAT DNA binding and Stat1
and Stat3 tyrosine phosphorylation (Fig. 4 D); the effects
on STAT phosphorylation were modest, likely secondary
to limited and transient ligation of Fc RI when F(ab )
fragments were used, but were consistently observed in five
experiments. Inhibition of IL-10 signaling by Fc RIII was
more limited, consistent with low level expression (Fig. 4
C), and cross-linking Fc RII had a minimal effect (Fig. 4
D, lane 4) that was not reproducibly detected in all experi-
ments. Thus, it is likely that IFN- –induced increased ex-
pression of Fc RI contributed to inhibition of IL-10 sig-
naling. These results indicate that crosstalk between Fc Rs
and IL-10Rs is regulated and that IFN-  activation couples
Fc Rs to inhibition of IL-10 signaling.
Inhibition of IL-10 Signaling Occurs via a Rapid, Direct
Pathway that Is Dependent upon Protein Kinase C. The
mechanism of inhibition of IL-10 signaling was investigated.
We first determined whether Fc R ligation inhibited proxi-
mal events in the IL-10 signaling pathway. Cell surface ex-
pression of IL-10Rs was measured by flow cytometry using
biotinylated IL-10. Cross-linking of Fc Rs led to a rapid
decrease in cell surface IL-10 binding sites on macrophages,
whereas incubation with anti-Fc R mAbs in the absence of
cross-linking had no effect (Fig. 5 A, and unpublished data).
Similar results were obtained using a mAb specific for IL-
10R1 (unpublished data), and surface expression of a control
protein, HLA-DR, was not affected by Fc R cross-linking
(Fig. 5 A). In contrast to cell surface IL-10R expression, to-
tal cellular expression of IL-10Rs did not change, as deter-
mined by immunoblotting of total cell lysates (Fig. 5 B).
This result suggests that Fc R cross-linking induced inter-
nalization of IL-10Rs, and is consistent with previous work
demonstrating rapid cycling of IL-10Rs between the cell
surface and intracellular compartments (49). Down-regula-
tion of cell surface IL-10R expression would be predicted to
diminish the activation of IL-10R–associated Jak1. Indeed,
activation of Jak1 was suppressed after Fc R ligation (Fig. 5
C). These results demonstrate that Fc R ligation inhibits
IL-10 signaling at a proximal step, upstream of STATs.
One major mechanism of inhibition of Jak-STAT signal-
ing at the level of cytokine receptors or Jaks is de novo ex-
Figure 3. Inhibition of IL-10 signal-
ing results in suppression of IL-10 activity.
(A) Fc R ligation suppresses IL-10-
mediated inhibition of cytokine produc-
tion. Es or E-IgGs were added to IFN- –
activated macrophages 1 h before
addition of IL-10 (20 ng/ml) and LPS
(100 ng/ml). Culture supernatants were
harvested 16 h later, and TNF-  and
IL-6 were measured using ELISA.
Three independent experiments were
performed and the total LPS-induced
TNF  and IL-6 production in the ab-
sence of IL-10 was 1.2 ng/ml and 3.4
ng/ml, respectively. (B) Inhibition of
IL-10–induced gene activation. Es or
E-IgGs were added to cells for 1 h fol-
lowed by a 3 h stimulation with IL-10
(20 ng/ml). mRNA levels were mea-
sured using real time PCR and normal-
ized relative to GAPDH mRNA.T
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pression of suppressors of cytokine signaling (SOCS; refer-
ence 50). The requirement for de novo production of
IL-10 signaling inhibitors was addressed by examining the
kinetics of inhibition, and by using actinomycin D and cy-
cloheximide to inhibit, respectively, de novo transcription
and translation. E-IgGs induced inhibition of IL-10 signaling
rapidly, within 20 min (Fig. 6 A), suggesting that inhibition
was direct, and did not depend upon synthesis of inhibitory
molecules. Inhibition of IL-10 signaling was preserved
when de novo gene expression was blocked using actino-
mycin D (Fig. 6, B and C; actinomycin D essentially com-
pletely blocked transcription in these cells at the concentra-
tions that were used [51]), and when de novo protein
synthesis was blocked using cycloheximide (unpublished
data). Additional experiments showed that culture superna-
tants from Fc R-stimulated macrophages did not inhibit
Figure 4. Fc R-induced inhibition of IL-10 signaling requires activation of macrophages with IFN- . (A) Macrophages were cultured with M-CSF or
IFN-  for 2 d, Es or E-IgGs were added for 1 h, and STAT activation was measured after a 10 min stimulation with IL-10 (20 ng/ml) using immunoblotting.
C, no erythrocytes were added. (B) Fc Rs were ligated for one hour using plate-bound IgG, and STAT activation was measured using immunoblotting. (C)
Macrophages cultured with M-CSF or IFN-  for 2 d were analyzed using flow cytometry. (D) Individual Fc Rs were cross-linked on IFN- –activated
macrophages using specific F(ab )s followed by F(ab )2 anti–mouse IgG, and STAT activation was measured using EMSA and immunoblotting.
Figure 5. Inhibition occurs at a proximal step in
IL-10 signal transduction. (A) Fc Rs were cross-
linked using specific mAbs and anti-mouse IgG for
1 h, and cell surface IL-10R and HLA DR expres-
sion was measured using biotinylated IL-10 or
FITC-conjugated anti-HLA DR mAb and flow
cytometry. (B) Total cell extracts from parallel wells
were analyzed for IL-10R1 expression using im-
munoblotting. (C) Cell extracts were analyzed for
pY-Jak1 and Jak1 by immunoblotting.T
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IL-10 signaling, thus indicating that Fc R ligation did not
result in the secretion of soluble inhibitors (unpublished
data). Taken together, these results indicate that induction
of inhibitory molecules, such as SOCS proteins, was not re-
quired for inhibition of IL-10 signaling. Instead, the results
suggest that inhibition occurs by a direct mechanism.
Our lab and others have described rapid and direct inhi-
bition of Jak-STAT signaling that is dependent upon mito-
gen-activated protein kinases (MAPKs), protein kinase C
(PKC), or proteosomes (51–55). Inhibition has been pro-
posed to occur by post-translational modification or degra-
dation of Jak-STAT signaling components. The role of
MAPKs, PKC, or proteosomes in inhibition of IL-10 sig-
naling was investigated using inhibitors of these kinases or
of proteosomes. Inhibitors of ERKs, p38, and proteosomes
had no effect (unpublished data). In contrast, GF109203X,
an inhibitor of PKC, reversed Fc R-mediated inhibition
of STAT DNA binding (Fig. 7 A) and tyrosine phosphory-
lation (Fig. 7 B). Inhibition of PKC reversed inhibition of
Jak1 tyrosine phosphorylation (Fig. 7 C), indicating that
PKC inhibited a proximal step in the IL-10 signaling path-
way. The ability of PKC to inhibit IL-10 signaling was fur-
ther tested using PMA, which activates PKC directly by
binding to the C1 zinc finger-containing domain (56).
PMA strongly blocked IL-10 signaling, and this inhibition
was reversed by GF109203X, which works at the PKC
ATP binding site (Fig. 7 D). Similar to Fc R cross-linking,
PMA suppressed cell surface IL-10R expression (Fig. 7 E).
These results indicate that Fc R ligation inhibits IL-10 sig-
naling by a direct pathway that utilizes PKC.
There are at least 9 different isoforms of PKC that have
been divided into conventional PKCs ( ,  ,  ; activated by
diacyl glycerol [DAG] and calcium), novel PKCs ( ,  ,  ,
 ; activated by DAG and not dependent on calcium), and
atypical PKCs ( ,  ; independent of DAG and calcium; ref-
erence 56). IFN-  activation of macrophages alters Fc R
signaling such that Fc Rs activate PKC  instead of PKC 
(57). Therefore, the role of PKC  in Fc R regulation of
IL-10 signaling was examined. PKC  activity was low in
M-CSF–cultured cells and was not increased by exposure to
Figure 6. Fc receptor-mediated inhibition of IL-10 signaling occurs rapidly and is independent of de novo gene expression. (A) Time course of inhi-
bition of IL-10 signaling. (B and C) Lack of reversal of inhibition of IL-10 signaling when de novo gene activation was blocked using actinomycin D (5
 g/ml). STAT activation was measured by EMSA (B) and immunoblotting (C).
Figure 7. Inhibition of IL-10 signaling is dependent upon PKC. (A–D) Reversal of inhibition of IL-10 signaling by the PKC inhibitor GF109203X.
GF109203X (1  M or as labeled) was added 20 min before adding Es or E-IgGs, and STAT activation was measured using EMSA with the hSIE oli-
gonucleotide (A and D) and immunoblotting for pY-Stat3 (B). Activation of Jak1 was measured by immunoblotting for pY-Jak1 (C). In D, PKC was
activated by adding PMA (50 ng/ml) 1 h before adding IL-10. (E) Cell surface IL-10R expression was measured using biotinylated IL-10 and flow cy-
tometry 1 h after adding PMA (50 ng/ml). Positive control, control macrophages not treated with anti-Fc R antibodies or PMA.T
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E-IgGs (Fig. 8 A). In contrast, baseline serine-phosphoryla-
tion of PKC  was substantially higher in IFN- –cultured
cells, and was further increased by exposure to E-IgGs (Fig.
8 A). E-IgGs also induced a striking activation of the 48 kD
highly active catalytic fragment of PKC  (reference 58; Fig.
8 A). IFN-  activation of macrophage cell lines has been
reported to couple Fc RI to activation of phosphatidy-
linositol 3-kinase (PI3K; reference 59), and PI3K has been
linked to the activation of PKC, including by Fc Rs (56,
59). Therefore, we investigated the role of PI3K in Fc R
inhibition of IL-10 signaling using the PI3K inhibitors
Wortmanin and LY294002. Inhibition of PI3K resulted in
a reversal of Fc R-mediated inhibition of IL-10 signaling
(Fig. 8 B). This result is consistent with IFN- –dependent
coupling of Fc Rs to the activation of PI3K and PKC, al-
though PI3K may also act via PKC-independent pathways.
The role of PKC  was further examined using elicited peri-
toneal macrophages from PKC  (60) deficient mice. Cross-
linking Fc Rs suppressed IL-10 signaling in wild-type and
control PKC -deficient mice (61; Fig. 8 C), and inhibition
was potentiated by the addition of PMA. In contrast, no in-
hibition of IL-10 signaling was detected in macrophages de-
ficient in PKC . These results demonstrate that inhibition
of IL-10 signaling by Fc Rs is dependent upon PKC .
Discussion
IL-10 is a major deactivator of myeloid cells, and IL-10
production and activity need to be tightly regulated to en-
sure the appropriate balance between clearance of pathogens
and avoidance of excessive tissue damage or autoimmunity
(1). We report that IL-10 signal transduction was blocked in
IFN- –activated macrophages when Fc Rs were ligated,
and in RA macrophages that exhibit an IFN- –activated
phenotype and are exposed to ICs in synovial fluid and tis-
sue (24, 62). These results establish that deactivation of mac-
rophages is regulated at the level of IL-10 signal transduc-
tion and suggest that defects in IL-10 signal transduction
may underlie previously reported diminished IL-10 activity
in RA, SLE, and chronic infection (12, 16, 17). Inhibition
of IL-10 signaling results in highly activated macrophages
that are resistant to suppression and are able to carry out
effector functions, even in the presence of high concen-
trations of IL-10. Excessive production of cytokines, che-
mokines and other inflammatory mediators by these macro-
phages would contribute to tissue damage and pathogenesis
of disease. One example would be inappropriately high pro-
duction of TNF-  in RA in the face of a homeostatic re-
sponse that includes elevated IL-10 production.
The lack of inhibition of IL-10 signaling by IL-1, LPS,
TNF- , GM-CSF, and TGF-  suggested that inhibition
was mediated by a pathway that is not activated by these
factors, but is activated by ICs via Fc Rs. Both pharmaco-
logic and genetic data indicated that inhibition was medi-
ated by PKC, specifically the   isoform of PKC that is acti-
vated by Fc Rs in IFN- –activated macrophages (56, 57),
but not by the other inflammatory stimuli that were exam-
ined. PKC  was modestly activated by IFN-  alone, and it
Figure 8. Role of PKC  in
Fc R-induced inhibition of IL-10
signaling. (A) Macrophages were
cultured with M-CSF or IFN- 
for 2 d, Es or E-IgGs were added
for 5 min, and PKC  activation
was measured using immuno-
blotting. (B) Wortmanin (30
nM) or LY294002 (10  M) was
added 20 min before adding
E-IgGs, and STAT activation
was measured using immuno-
blotting for pY-Stat3. (C) Elic-
ited peritoneal macrophages from
control wild-type mice and mice
deficient in PKC  or PKC 
were activated with IFN-  for
2 d, incubated with Es opsonized
with anti-Fc R mAb 2.4G2
(E-IgG) or with murine IgG
(E-mIgG) and PMA (50 ng/ml)
for 1 h, and stimulated with
IL-10. STAT activation was
measured using immunoblotting.T
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is possible that this pool of active PKC  contributed to in-
hibition of IL-10 signaling by coactivating a Fc R-induced
pathway. Inhibition mediated by PKC  did not require de
novo synthesis of inhibitory molecules, or secretion of pre-
formed inhibitors. This suggests that PKC, or molecules
activated downstream of PKC, directly modify and inacti-
vate IL-10 Jak-STAT signaling components. Activation of
PKC by either Fc Rs or PMA resulted in decreased cell
surface expression of IL-10R, but total cellular IL-10R lev-
els did not change (Fig. 5, and unpublished data). The IL-
10R1 subunit contains a consensus dileucine internalization
motif preceded by a serine that corresponds to a consensus
PKC phosphorylation site (1, 63), and the IL-10R has been
shown to partition between the cell surface and an intracel-
lular pool (49). Thus, the results suggest that PKC induces
internalization of IL-10Rs by phosphorylation of the IL-
10R1 internalization motif, similar to PKC-dependent
phosphorylation and internalization of other cell surface re-
ceptors (64). Decreased Jak1 activation could be explained
by decreased IL-10R cell surface expression. However,
PKC  has been shown to inactivate Jaks via phosphoryla-
tion (65), and it is also possible that direct phosphorylation
of IL-10R–associated Jaks contributes to inhibition of IL-
10 signaling. A role for PKC-dependent activation of
ERKs or production of reactive oxygen intermediates was
ruled out (unpublished data).
An interesting question is how activation of macro-
phages with IFN-  couples Fc Rs to inhibition of IL-10
signaling. Ligation with Fc R isoform-specific reagents
showed that Fc RI and, to a lesser extent, Fc RIII, inhib-
ited IL-10 signaling. Because Fc RI and Fc RIII signal via
the receptor-associated ITAM-containing FcR  common
signaling subunit (18), and thus activate similar signal trans-
duction pathways, it is possible that the weak inhibitory ef-
fect mediated by Fc RIII was secondary to low cell surface
expression that was not increased by IFN-  (Fig. 4 C).
IFN-  treatment resulted in increased expression of Fc RI
and thus quantitatively increased signaling via Fc RI after
IFN-  activation likely contributed to inhibition of IL-10
signaling. In addition to modulating Fc RI expression,
IFN-  has been reported to increase coupling of Fc RI
with ITAM-containing FcR  (18, 66), with concomitant
activation PI3K and PKC  (57, 59). Thus, a qualitative
change in Fc R signaling that induced activation of PKC 
was also important for inhibition of IL-10 signaling.
Inhibition of IL-10 signaling required exposure of mac-
rophages to products of both cellular and humoral im-
munity, IFN-  and antibodies complexed with antigens.
Thus, during the course of a normal immune response,
generation of macrophages refractory to inhibition by IL-
10 will be transient and such cells will only be generated
when the immune system is fully active and maximal effec-
tor function is required. In contrast, several autoimmune
and inflammatory diseases, such as SLE and RA (19, 24),
are characterized by chronic production of IFN-  and ICs.
Our results suggest that chronic production of IFN-  and
ICs will lead to the ongoing generation of macrophages
with defects in IL-10 signal transduction. These defects in
IL-10 signaling and activity will result in diminished ability
of IL-10 to suppress TNF-  production, thus shifting cy-
tokine balance toward increased TNF-  and inflammation.
Fc Rs have been strongly implicated in the pathogenesis of
arthritis in animal models of RA (24, 26–33), and RA joint
macrophages show evidence of activation by IFN-  and
are exposed to high levels of immune complexes (62).
While it is possible that several mechanisms contribute to
suppressed IL-10 signaling in RA, our data suggest that in-
hibition mediated by Fc Rs plays a role, especially as IL-
10R expression is low in RA macrophages (unpublished
data), similar to low IL-10R expression after Fc R ligation
(Fig. 5). Diminished responsiveness to IL-10, and thus in-
adequate suppression of macrophage function, may con-
tribute to chronicity and severity of inflammation in RA.
In addition, diminished ability of joint macrophages to re-
spond to IL-10 helps explain the lack of efficacy of exoge-
nous IL-10 in the treatment of RA (67).
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